{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:58:34Z","timestamp":1787313514623,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00277-024-06037-8","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:01:51Z","timestamp":1729123311000},"page":"1259-1267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel use of Siltuximab in a patient with VEXAS Syndrome"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0607-0316","authenticated-orcid":false,"given":"Beatriz","family":"C\u00e1ceres-Nazario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-6677","authenticated-orcid":false,"given":"Joshua","family":"Rivenbark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5568-4441","authenticated-orcid":false,"given":"Samuel M.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"6037_CR1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383:2628\u20132638. https:\/\/doi.org\/10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"6037_CR2","doi-asserted-by":"publisher","first-page":"e15050","DOI":"10.1111\/exd.15050","volume":"33","author":"AJ Saad","year":"2024","unstructured":"Saad AJ, Patil MK, Cruz N, Lam CS, O\u2019Brien C, Nambudiri VE (2024) VEXAS syndrome: a review of cutaneous findings and treatments in an emerging autoinflammatory disease. Exp Dermatol 33:e15050. https:\/\/doi.org\/10.1111\/exd.15050","journal-title":"Exp Dermatol"},{"key":"6037_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.5582\/irdr.2023.01020","volume":"12","author":"S Kobak","year":"2023","unstructured":"Kobak S (2023) VEXAS syndrome: current clinical, diagnostic and treatment approaches. Intractable Rare Dis Res 12:170\u2013179. https:\/\/doi.org\/10.5582\/irdr.2023.01020","journal-title":"Intractable Rare Dis Res"},{"key":"6037_CR4","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1182\/blood.2020010177","volume":"137","author":"E Bourbon","year":"2021","unstructured":"Bourbon E, Heiblig M, Gerfaud Valentin M et al (2021) Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood 137:3682\u20133684. https:\/\/doi.org\/10.1182\/blood.2020010177","journal-title":"Blood"},{"key":"6037_CR5","doi-asserted-by":"publisher","first-page":"eabi6794","DOI":"10.1126\/sciadv.abi6794","volume":"7","author":"P Tao","year":"2021","unstructured":"Tao P, Wang S, Ozen S et al (2021) Deubiquitination of proteasome subunits by OTULIN regulates type I IFN production. Sci Adv 7:eabi6794. https:\/\/doi.org\/10.1126\/sciadv.abi6794","journal-title":"Sci Adv"},{"key":"6037_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaci.2021.05.014","volume":"149","author":"CI van der Made","year":"2022","unstructured":"van der Made CI, Potjewijd J, Hoogstins A et al (2022) Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS. J Allergy Clin Immunol 149:432\u2013439e4. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.014","journal-title":"J Allergy Clin Immunol"},{"key":"6037_CR7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2016.07.019","volume":"166","author":"RB Damgaard","year":"2016","unstructured":"Damgaard RB, Walker JA, Marco-Casanova P et al (2016) The deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity. Cell 166:1215\u20131230e20. https:\/\/doi.org\/10.1016\/j.cell.2016.07.019","journal-title":"Cell"},{"key":"6037_CR8","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","volume":"62","author":"Z Boyadzhieva","year":"2023","unstructured":"Boyadzhieva Z, Ruffer N, K\u00f6tter I, Krusche M (2023) How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology (Oxford) 62:3518\u20133525. https:\/\/doi.org\/10.1093\/rheumatology\/kead240","journal-title":"Rheumatology (Oxford)"},{"key":"6037_CR9","doi-asserted-by":"publisher","first-page":"C1121","DOI":"10.1152\/ajpcell.00356.2021","volume":"323","author":"R Henrie","year":"2022","unstructured":"Henrie R, Cherniawsky H, Marcon K et al (2022) Inflammatory diseases in hematology: a review. Am J Physiol Cell Physiol 323:C1121\u2013C1136. https:\/\/doi.org\/10.1152\/ajpcell.00356.2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"6037_CR10","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood.2021011455","volume":"137","author":"PC Grayson","year":"2021","unstructured":"Grayson PC, Patel BA, Young NS (2021) VEXAS syndrome. Blood 137:3591\u20133594. https:\/\/doi.org\/10.1182\/blood.2021011455","journal-title":"Blood"},{"key":"6037_CR11","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","volume":"5","author":"IE Obiorah","year":"2021","unstructured":"Obiorah IE, Patel BA, Groarke EM et al (2021) Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 5:3203\u20133215. https:\/\/doi.org\/10.1182\/bloodadvances.2021004976","journal-title":"Blood Adv"},{"key":"6037_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1182\/blood-2023-187454","volume":"142","author":"BA Patel","year":"2023","unstructured":"Patel BA, Ferrada M, Quinn K et al (2023) Clinical manifestations are evolving and progressive in patients with VEXAS syndrome. Blood 142:703. https:\/\/doi.org\/10.1182\/blood-2023-187454","journal-title":"Blood"},{"key":"6037_CR13","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. Supplementary appendix. N Engl J Med 383:2628\u20132638. https:\/\/doi.org\/10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"6037_CR14","doi-asserted-by":"publisher","first-page":"e002255","DOI":"10.1136\/rmdopen-2022-002255","volume":"8","author":"MY Khitri","year":"2022","unstructured":"Khitri MY, Guedon AF, Georgin-Lavialle S et al (2022) Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open 8:e002255. https:\/\/doi.org\/10.1136\/rmdopen-2022-002255","journal-title":"RMD Open"},{"key":"6037_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle S, Terrier B, Guedon AF et al (2022) Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol 186:564\u2013574. https:\/\/doi.org\/10.1111\/bjd.20805","journal-title":"Br J Dermatol"},{"key":"6037_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ajh.27156","volume":"99","author":"MJ Koster","year":"2024","unstructured":"Koster MJ, Lasho TL, Oltneau H et al (2024) VEXAS syndrome: clinical, hematologic features and a practical approach to diagnosis and management. Am J Hematol 99:284\u2013299. https:\/\/doi.org\/10.1002\/ajh.27156","journal-title":"Am J Hematol"},{"key":"6037_CR17","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood.2020010286","volume":"137","author":"JA Poulter","year":"2021","unstructured":"Poulter JA, Collins JC, Cargo C et al (2021) Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood 137:3676\u20133681. https:\/\/doi.org\/10.1182\/blood.2020010286","journal-title":"Blood"},{"key":"6037_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jdcr.2022.02.022","volume":"23","author":"A Goyal","year":"2022","unstructured":"Goyal A, Narayanan D, Wong W et al (2022) Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome. JAAD Case Rep 23:15\u201319. https:\/\/doi.org\/10.1016\/j.jdcr.2022.02.022","journal-title":"JAAD Case Rep"},{"key":"6037_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ajh.26455","volume":"97","author":"MM Patnaik","year":"2022","unstructured":"Patnaik MM, Tefferi A (2022) Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97:352\u2013372. https:\/\/doi.org\/10.1002\/ajh.26455","journal-title":"Am J Hematol"},{"key":"6037_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ajh.27169","volume":"99","author":"C Gurnari","year":"2024","unstructured":"Gurnari C, Pascale MR, Vitale A et al (2024) Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort. Am J Hematol 99:254\u2013262. https:\/\/doi.org\/10.1002\/ajh.27169","journal-title":"Am J Hematol"},{"key":"6037_CR21","doi-asserted-by":"publisher","unstructured":"Trikha R, Kong KL, Galloway J et al (2024) De-escalation of corticosteroids and clonal remission in UBA1 mutation-driven VEXAS syndrome with 5-azacytidine. Haematologica. Online ahead of print.\u00a0https:\/\/doi.org\/10.3324\/haematol.2024.285519","DOI":"10.3324\/haematol.2024.285519"},{"key":"6037_CR22","doi-asserted-by":"publisher","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","volume":"10","author":"T Tanaka","year":"2018","unstructured":"Tanaka T, Nazaraki M, Kishimoto T (2018) IL-6 immunotherapy. Cold Spring Harb Perspect Biol 10:a028456. https:\/\/doi.org\/10.1101\/cshperspect.a028456","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6037_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/1744666X.2021.1919086","volume":"17","author":"N Potere","year":"2021","unstructured":"Potere N, Batticciotto A, Vecchi\u00e9 A et al (2021) The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol 17:601\u2013618. https:\/\/doi.org\/10.1080\/1744666X.2021.1919086","journal-title":"Expert Rev Clin Immunol"},{"key":"6037_CR24","unstructured":"Actemra. Prescribing information. Genentech; December 2022. Accessed May 7 (2024).\u00a0\u00a0https:\/\/www.gene.com\/download\/pdf\/actemra_prescribing.pdf"},{"key":"#cr-split#-6037_CR25.1","unstructured":"Sylvant (2024) Prescribing information. EUSA Pharma"},{"key":"#cr-split#-6037_CR25.2","unstructured":"December 2019. Accessed May 7.\u00a0https:\/\/sylvant.com\/wp-content\/themes\/sylvant_dtc\/assets\/docs\/sylvant-prescribing-info.pdf"},{"key":"6037_CR26","doi-asserted-by":"publisher","first-page":"678927","DOI":"10.3389\/fimmu.2021.678927","volume":"12","author":"F Staels","year":"2021","unstructured":"Staels F, Betrains A, Woei-A-Jin FJSH et al (2021) Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome. Front Immunol 12:678927. https:\/\/doi.org\/10.3389\/fimmu.2021.678927","journal-title":"Front Immunol"},{"key":"6037_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","volume":"9","author":"NR Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas NR, O\u2019Shaughnessy MM, O\u2019Regan JA et al (2014) C3 glomerulopathy: clinical pathologic features and predictors of outcome. Clin J Am Soc Nephrol 9:46\u201353. https:\/\/doi.org\/10.2215\/CJN.04700513","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06037-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T17:56:28Z","timestamp":1743875788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06037-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6037"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06037-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4952720\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Office of Human Research Ethics at the University of North Carolina Chapel Hill has issued a determination that the research presented here does not constitute human subjects research as defined under federal regulations and does not require institutional review board (IRB) approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The participant has consented to the submission of the case report to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Joshua Rivenbark: Research support from Agios; Manish K. Saha: Honoraria from Calliditas, Travere, ChemoCentryx, and Elsevier; Samuel M. Rubinstein: Ad-hoc consulting with EUSA pharma, Janssen, BMS, Sanofi, Lava Therapeutics; Beatriz C\u00e1ceres-Nazario and Stephanie Mathews have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}